Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells.

Lapinska K, Housman G, Byler S, Heerboth S, Willbanks A, Oza A, Sarkar S.

Anticancer Res. 2016 Nov;36(11):5731-5742.

PMID:
27793894
2.

Cultivating Interest in Oncology Through a Medical Student Oncology Society.

Agarwal A, Shah A, Byler S, Hirsch AE.

J Cancer Educ. 2017 Mar;32(1):31-34. doi: 10.1007/s13187-015-0902-4.

PMID:
26341219
3.

EMT and tumor metastasis.

Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A, Sarkar S.

Clin Transl Med. 2015 Feb 26;4:6. doi: 10.1186/s40169-015-0048-3. eCollection 2015.

4.

Drug resistance in cancer: an overview.

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S.

Cancers (Basel). 2014 Sep 5;6(3):1769-92. doi: 10.3390/cancers6031769. Review.

5.

Do epigenetic drug treatments hold the key to killing cancer progenitor cells?

Byler S, Sarkar S.

Epigenomics. 2014 Apr;6(2):161-5. doi: 10.2217/epi.14.4. No abstract available.

PMID:
24811783
6.

Genetic and epigenetic aspects of breast cancer progression and therapy.

Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S.

Anticancer Res. 2014 Mar;34(3):1071-7. Review.

PMID:
24596345
7.

Cancer development, progression, and therapy: an epigenetic overview.

Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M.

Int J Mol Sci. 2013 Oct 21;14(10):21087-113. doi: 10.3390/ijms141021087. Review.

8.

Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy.

Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S.

Epigenomics. 2013 Feb;5(1):87-94. doi: 10.2217/epi.12.68. Review.

PMID:
23414323

Supplemental Content

Loading ...
Support Center